« Back
Home /
Atorvastatin

Atorvastatin

Item no.	HY-B0589-100mg
Manufacturer	MedChem Express
CASRN	134523-00-5
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 50 mg
Category	Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.82
Citations	[1]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82.\|[2]Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22.\|[3]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61.\|[4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72.\|[5] Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821.\|[6]Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42(5):409-415. Acta Pharmacol Sin. 2024 Mar 8.\|Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658.\|Biomed Pharmacother. 2023 Aug 12;166:115323.\|Biotechnol Bioeng. 2021 Sep 3.\|Cancer Lett. 2022 Oct 19;215976.\|Cell Cycle. 2019 Dec;18(23):3337-3350.\|Cell Cycle. 2021 Sep 8;1-14.\|Emerg Microbes Infect. 2025 Feb 19:2470371.\|Endocrinology. 2022 May 18;bqac076.\|Eur J Pharmacol. 2023 Aug 1;956:175938.\|Eur J Pharmacol. 2023 Dec 21:176261.\|Eur J Pharmacol. 2025 Feb 5:177357.\|Exp Cell Res. 2023 Oct 23:113829.\|Front Cell Dev Biol. 2022 Mar 3;10:806081.\|Inflammation. 2024 Oct 31.\|Int J Mol Sci. 2023 Apr 19, 24(8), 7492.\|J Appl Toxicol. 2024 Apr 19\|J Appl Toxicol. 2024 Apr 19.\|J Mol Neurosci. 2021 Sep 26.\|J Nat Prod. 2022 Jun 24.\|J Neuroimmunol. 2020 Oct 24;350:577429.\|J Tradit Complement Med. 2024 Mar 29.\|Life Sci. 2025 Mar 17:123571.\|Med Gas Res. 2024 March 28.\|MedComm. 2024 Aug 31.\|Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.\|Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun 8.\|Oncogene. 2022 Oct 31.\|Orebro University. 2024.\|Phytomedicine. 2023 Jul 26;119:154997.\|Proteomics. 2023 May 4;e2300041.\|Research Square Preprint. 2021 Dec.\|Research Square Preprint. 2022 Jun.\|Research Square Preprint. 2024 Apr 9.\|Sci Rep. 2020 Jan 28;10(1):1308.\|Signal Transduct Target Ther. 2023 Dec 25;8(1):457.\|Adv Sci (Weinh). 2024 Jul 5:e2403451.\|Arch Biochem Biophys. 2025 Jan 21:765:110316.\|bioRxiv. 2024 Jul 3:2024.07.01.601474.\|Cell Death Dis. 2021 May 13;12(5):482.\|Endocrinology. 2018 May 1;159(5):2008-2021.\|Free Radic Biol Med. 2024 May 2:S0891-5849(24)00435-0.\|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.\|Pharmaceutics. 2022, 14(1), 176.\|Eur J Med Chem. 2024 Dec 5.
Smiles	O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	134523-00-5
Similar products	134523-00-5
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Autophagy; HMG-CoA Reductase (HMGCR)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	558.64
Product Description	Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].
Manufacturer - Research Area	Metabolic Disease; Inflammation/Immunology; Cancer
Solubility	DMSO: ≥ 100 mg/mL
Manufacturer - Pathway	Autophagy; Metabolic Enzyme/Protease
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B0589-100mg-safety-datasheet.pdf